or Try an Advanced Search...

    Treatment Of Cancer Stocks List

    Symbol Grade Name % Change
    CASI D CASI Pharmaceuticals, Inc. -0.19
    MURA D Mural Oncology plc -2.96
    LPTX D LEAP THERAPEUTICS, INC. -3.09
    MRKR D Marker Therapeutics, Inc. -6.27
    NVCT D Nuvectis Pharma, Inc. -2.76
    MEIP D MEI Pharma, Inc. 1.43
    KPTI D Karyopharm Therapeutics Inc. -0.81
    CLDX D Celldex Therapeutics, Inc. -0.13
    MGNX D MacroGenics, Inc. -2.13
    PRPO F Precipio, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
    Related Stock Lists: Cancer Biopharmaceutical Biotechnology Life Sciences Lymphoma Medicine Solid Tumors Clinical Medicine Health Sciences Advanced Solid Tumors Autoimmune Disease Drug Discovery Drugs Immunology Immunotherapies Pharmacy Virotherapy Achondroplasia Acute Myeloid Leukemia Adoptive Cell Transfer

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Cancer stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 8.13
    PBE D PowerShares Dynamic Biotech & Genome 7.64
    BBP C BioShares Biotechnology Products Fund 5.16
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 5.13
    FBT D First Trust Amex Biotech Index Fund 4.51
    View all Treatment Of Cancer ETFs...
    Compare ETFs
    Compare BBP to FBT Compare IDNA to BBP Compare SURI to FBT

        Treatment Of Cancer Stocks Recent News

        Date Stock Title
        Nov 20 KPTI Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
        Nov 20 CLDX Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
        Nov 20 CLDX Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
        Nov 18 KPTI Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
        Nov 17 MRKR Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 17 MEIP Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 15 CASI CASI Pharmaceuticals reports Q3 results
        Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
        Nov 15 NVCT Nuvectis Pharma reports data from Phase 1b study of NXP800
        Nov 14 MRKR Marker Therapeutics GAAP EPS of -$0.26, revenue of $1.93M
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
        Related Stock Lists: Cancer Biopharmaceutical Biotechnology Life Sciences Lymphoma Solid Tumors Cell Therapy Clinical Medicine Disease Hematological Malignancies Monoclonal Antibody Pharmaceutical Products Protein Kinase Inhibitor Small Molecule Therapies Tyrosine Kinase Acute Leukemia Adoptive Cell Transfer Advanced Solid Tumors Aging Associated Diseases Anaplastic Lymphoma Kinase
        Treatment Of Cancer

        Treatment of cancer depends on the type and stage of the cancer, as well as the patient's overall health and preferences. Treatment options may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and/or hormone therapy. In some cases, a combination of treatments may be used.

        Browse All Tags